Raptor Pharmaceutical (NASDAQ:RPTP) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2 by 6 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 3 Brokerage Firms have advised hold.
Other Equity analysts have also commented on the company shares. JMP Securities upgrades its rating on Raptor Pharmaceutical (NASDAQ:RPTP). Analysts at the JMP Securities have a current rating of Market Outperform on the shares. The shares were previously rated Market Outperform. The rating by the firm was issued on April 7, 2016.
Raptor Pharmaceutical (NASDAQ:RPTP): According to 5 Analysts, The short term target price has been estimated at $ 7.6.The target price could deviate by a maximum of $2.7 from the forecast price. In the near term, the target price could hit a high of $11 and a low of $ 4.
Raptor Pharmaceutical (NASDAQ:RPTP) witnessed a decline in the market cap on Tuesday as its shares dropped 5.74% or 0.31 points. After the session commenced at $5.41, the stock reached the higher end at $5.41 while it hit a low of $5.07. With the volume soaring to 825,500 shares, the last trade was called at $5.09. The company has a 52-week high of $16.28. The company has a market cap of $434 million and there are 85,306,787 shares in outstanding. The 52-week low of the share price is $2.94.
Raptor Pharmaceuticals Corp. has lost 6.78% in the last five trading days and dropped 2.12% in the last 4 weeks. Raptor Pharmaceuticals Corp. is up 11.87% in the last 3-month period. Year-to-Date the stock performance stands at -2.12%.
Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Companys product, PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine, received a marketing authorization from the European Commission (EC), as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Companys pipeline includes its delayed-release form of cysteamine, or RP103 and its oral 4-methylpyrazole, or Convivia. Its other product, Quinsair, is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.